Change in DAS28 scores and EULAR response criteria following 6 months of anti-TNF therapy in anti-CEP-1, anti-cVim, and anti-cFib antibody-positive and negative patients with RA. Values indicate number (%) or mean (SD). Linear regression adjusted for baseline DAS28, concomitant DMARD, sex, HAQ, and smoking.
| Anti-CEP-1 | Anti-cVim | Anti-cFib | ||||
|---|---|---|---|---|---|---|
| Negative, n = 276 | Positive, n = 174 | Negative, n = 252 | Positive, n = 184 | Negative, n = 108 | Positive, n = 328 | |
| Baseline DAS28 (SD) | 6.57 (0.94) | 6.56 (0.93) | 6.58 (0.96) | 6.54 (0.91) | 6.60 (0.99) | 6.55 (0.92) |
| Change in DAS28 (SD) | −2.50 (1.52) | −2.41 (1.58) | −2.50 (1.53) | −2.43 (1.57) | −2.78 (1.50) | −2.37 (1.55) |
| Linear regression coefficient (95% CI) | 0.04 (−0.24, 0.32), p = 0.77 | 0.06 (−0.22, 0.33), p = 0.69 | 0.37 (0.06, 0.69), p = 0.02 | |||
| No response (%) | 57 (20.7) | 39 (22.4) | 54 (21.4) | 38 (20.7) | 20 (18.5) | 72 (22.0) |
| Moderate response (%) | 140 (50.7) | 89 (51.2) | 127 (50.4) | 95 (51.6) | 51 (47.2) | 171 (52.1) |
| Good response (%) | 79 (28.6) | 46 (26.44) | 71 (28.2) | 51 (27.7) | 37 (34.3) | 85 (25.9) |
DAS28: Disease Activity Score-28; DMARD: disease-modifying antirheumatic drug; HAQ: Health Assessment Questionnaire.